The 6th NextGen Conference China to Open Soon

News provided by

Mar 23, 2016, 10:24 ET

SHANGHAI, March 23, 2016 /PRNewswire/ -- Based on the data analysis from CFDA that there are around 5,000 pharmaceutical manufacturers in China in total, and 90% of them manufacture generics. There will be big changes and great adjustment around the year of 2018 due to the changeable policy and market environment.

Hosted by UBM, The 6th NEXTGEN CHINA 2016 will gather all resources of CPhI global and use the past five conferences to explore the above topics and showcase the evolving generics landscape and solutions.

The 6th NextGen Conference China to Open Soon

More than 50 guests have registered for the conference, such as Huahai Pharmaceutical Co., Ltd., Luye Pharma Group, NOVARTIS, Merro, Zhijun Pharmaceutical, WANHUA, BeiLu Pharmaceutical and Pfizer. Catch the Early Bird Deadline before March 25 with the online registration.

Conference Time: April 12-13, 2016
Conference Location: Ballroom in 3F, New World Shanghai Hotel

Hot Speakers and Topics:

Clarifying and solutions: generics consistency evaluation on quality and efficacy
Professor Bo Wang, Researcher, The Research Center of National Drug Policy & Ecosystem
Implementation and forecast: opportunities for generics manufacturers
Yazhou Sun, Guest Professor, CFDA Institute of Executive Development
Drug Marketing Authorization Holder (MAH), feasibility analysis in China
Professor Yue Yang, Vice Director, College of Business Administration of Shenyang Pharmaceutical University
Monitor of all life cycle in generics quality consistency evaluation
Yueping Sun, WHO Consultant, with 12 years experiences in pharmacology research & 25 years experience with pharmaceutical companies and medical consultation
Strategic cooperation and M&A-how to seek for new chances for generics manufacturers
John Wang, Partner, Pharma Investor, GTJA Investment Group
Promoting the internationalization of China-made Generics by synergizing both internal and external capabilities
Shizhong Luo, General Manager, Beijing Yabao International Trade Co., Ltd
Intellectual property strategy in generics development process
Yunli Xue, Vice President of Pharma IP, Luye Pharma
How to perform meaningful forced degradation studies and the strategies for developing stability-indicating analytical methods
Min Li, PhD, VP of Analytical Operation, Huahai Pharmaceutical Co., Ltd
Liquid chromatography method and impurity profile research method of generics
Baiming Xiao, PhD, Executive Technology Director, Research Institute of Simcere
CMC strategy in impurity control for irinotecan HCI trihydrate salt
Jason Liou, PhD, Senior Director of CMC, Hansyn Pharma
Governing principles of BE testing
Yuhu Zhang, Chief Pharmacist & Senior Reviewer (Retired), Center for Drug Evaluation of CFDA
Guiding significance of in vitro dissolution testing on BE testing
Xiaoming Wu, Deputy General Manager, Pioneer Pharma
Challenges and replies of standardization biological analysis in BE
Xiaohang Shen, PhD, Biological Analysis Expert & CFDA Consultant

Who Will Attend:

Decision Makers, R&D, Regulatory Affairs, Marketing, BD, QA/QC and Manufactures
Generics/Biosimilar Manufacturers, Government/Regulatory/Association/Researchers, Innovators Pharma Manufacturers, API, Ingredient & Material, Equipment/Service/IT/PAT Suppliers, CRO/CMO

Download the complete agenda
Download the previous post-conference report
Online Registration

Ms. Julia Zhu
+86-21-6157-3922
[email protected]

Photo - http://photos.prnewswire.com/prnh/20160323/347219

SOURCE The 6th NextGen Conference